Valt

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valt

Quick Facts: Valt (Valsartan)

Property Description
Active Ingredient Valsartan
Form Oral tablets, Oral suspension
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Origin Synthetic, Nonpeptide
General Purpose Managing elevated systemic blood pressure

Valt: Defining its Pharmacological Identity

Valt is a trade name for the medication containing the active ingredient Valsartan, which is a synthetic, nonpeptide compound classified as an Angiotensin II Receptor Blocker (ARB). This classification confirms its role in targeting a key cardiovascular regulation pathway. The medicine is primarily administered via the oral route, prepared either as solid tablets or as a liquid oral suspension. The flexibility of the oral suspension form is a distinguishing feature that can facilitate precise dosing, particularly in certain patient groups, such as children aged 1 and older.


What is an Angiotensin II Receptor Blocker (ARB)?

An ARB is a specific type of antihypertensive agent whose general purpose is to lower elevated systemic blood pressure by promoting vascular relaxation. The drug works by modulating the renin-angiotensin-aldosterone system (RAAS), a crucial hormonal pathway that controls vascular tone. By interrupting the signaling that leads to blood vessel constriction, Valsartan effectively reduces resistance to blood flow, thereby decreasing the cardiac workload required to pump blood throughout the body. As a class, ARBs are used for the management of blood pressure and the reduction of cardiovascular risks.


Valsartan vs. Related Antihypertensive Types

Valsartan's mechanism differentiates it from Angiotensin-Converting Enzyme (ACE) Inhibitors, which represent another major class of RAAS-modulating drugs. While ACE inhibitors block the enzyme that forms the potent constricting hormone Angiotensin II, Valsartan acts later in the pathway by specifically blocking the AT1 receptor where Angiotensin II exerts its effects. This targeted difference frames Valsartan's class as a distinct, specific strategy for long-term blood pressure management and cardiovascular support, offering an important alternative mechanism for modulating the RAAS.

What side effects are possible with Valt?

Possible Side Effects and Safety Information

The safety profile of Valt (valsartan), an Angiotensin II Receptor Blocker, is documented through official government regulatory sources, which classify potential adverse reactions primarily by frequency and the organ system affected.

Adverse Reaction Classification

Side effects observed in clinical studies are grouped based on the frequency of occurrence:

  • Common Reactions: These generally include events such as dizziness, headache, fatigue, back pain, and diarrhea. For patients using Valt for heart failure, hypotension (low blood pressure) and hyperkalemia (elevated potassium levels) are also classified as common. The overall profile includes effects on the Nervous, Gastrointestinal, and Musculoskeletal Systems.
  • Uncommon Reactions: Less frequent reactions documented in regulatory documents include vertigo, cough, nausea, and abdominal pain.

Serious Safety Concerns

The most significant safety constraint is the official Boxed Warning for Fetal Toxicity. Regulatory documents explicitly state that drugs acting on the renin-angiotensin-aldosterone system (RAAS), including Valsartan, can cause injury and death to a developing fetus and are contraindicated during the second and third trimesters of pregnancy. Rare, but serious, post-marketing reactions have been reported, including Angioedema (swelling of the face, lips, and tongue) and Hepatitis.

Population-Specific Restrictions

Specific limitations exist for certain groups. The use of Valt is contraindicated in patients with severe hepatic impairment (severe liver function issues). Additionally, co-administration with aliskiren is contraindicated in patients diagnosed with diabetes due to an increased risk of renal impairment, hypotension, and hyperkalemia. Symptomatic hypotension may occur in rare instances upon the initiation of therapy, especially in patients with pre-existing salt or volume depletion.

Overdose and Emergency Response

Valt Overdose and When to Seek Help

Official regulatory documentation defines the acute risk of overdosage based on the drug's primary pharmacological action. The most likely manifestation of an overdose is marked hypotension (severely low blood pressure). This profound hemodynamic effect may be accompanied by symptoms such as dizziness and, less commonly, changes in heart rate, including tachycardia or bradycardia.

Documented Severe Outcomes and Required Actions

Overdosage may lead to severe, life-threatening outcomes, including severe hypotension escalating to circulatory collapse (shock) and potentially acute renal failure. Due to this risk, official labeling mandates that any suspected overdose requires that a person seek immediate medical attention. The required action is to contact emergency services immediately or call a Poison Control Center.

Supportive Management and Monitoring

The management of Valt overdosage is strictly symptomatic and supportive. Regulatory summaries confirm that no specific antidote is known for valsartan. Because valsartan is highly protein-bound, it is considered unlikely to be removed by hemodialysis.

Supportive measures documented in official sources include procedures such as gastric lavage and the use of activated charcoal if administered shortly after ingestion. If severe hypotension occurs, treatment may include the intravenous infusion of normal sodium chloride solution to restore volume and pressure.

Therapeutic Uses of Valt

What Valt Treats: Main Uses and Benefits

The primary therapeutic applications of Valt (valsartan) are focused on long-term cardiovascular support and the management of chronic conditions, addressing three primary areas of heart health.

Valt is commonly used to help manage high blood pressure (hypertension), to provide therapeutic support for chronic heart failure, and for cardiovascular support in clinically stable patients post-heart attack. This use is generally considered relevant for long-term management, aiming to support stable systemic pressure and assist the function of a weakened heart.


Sustained Control and Support

Using Valt may assist in supporting stable systemic pressure, which may assist with managing the risk of major cardiovascular events. Furthermore, its application may assist with managing symptom clusters associated with heart issues, such as fatigue and shortness of breath. This therapeutic approach supports the patient's general comfort and functional stability in daily life.

“This type of therapy is generally considered relevant for supporting the patient across chronic cardiovascular conditions.”


Quick Fact: Relief for Systemic Strain
Primary Therapeutic Goal Achieving and maintaining stable systemic pressure.
Symptom Clusters Addressed Elevated vascular strain, fatigue, and shortness of breath associated with cardiac stress.
Key Patient Benefit Assists with maintaining functional stability and managing the risk of major cardiovascular events.

Eligibility and Restrictions for Use

Who Can and Cannot Use Valt?

This section details the population eligibility rules for Valt (valsartan), strictly based on official government regulatory documents.

Eligibility Status Patient Populations Defined by Regulators
Allowed Use Adults (18+) for all labeled indications, and pediatric patients aged 6–16 for hypertension only. Use in older adults is generally permitted.
Contraindicated Use Use is strictly prohibited for patients with known hypersensitivity to valsartan. It is also contraindicated in the second or third trimesters of pregnancy, and in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis. Absolute non-eligibility applies to patients with diabetes or moderate-to-severe renal impairment concurrently taking an Aliskiren-containing medicine.
Restricted/Limited Use Valt is not recommended for women who are breastfeeding or for children under 6 years of age (contraindicated under 1 year). Caution is required for patients with mild-to-moderate hepatic impairment or severe renal impairment, where use is subject to specific regulatory limits.

Connection to the overall eligibility profile: Official government regulatory documents define who can and cannot use Valt through clear, non-advisory constraints that govern use based on life stage, pre-existing organ disease, and specific co-medication rules.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Valt

Interaction Scope

Classification Interacting Medicines/Substances Interaction Outcome (Officially Documented)
Contraindicated Aliskiren Forbidden co-administration in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m²), due to dual blockade of the Renin-Angiotensin System (RAS).
Pharmacodynamic Potassium-Sparing Diuretics (e.g., spironolactone), Potassium Supplements, Heparin Additive effect leading to an increased risk of hyperkalemia (elevated serum potassium levels). This risk is also noted with potassium-containing salt substitutes.
Pharmacodynamic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 Inhibitors May lead to an attenuation (reduction) of the antihypertensive effect and increase the risk of renal function deterioration.
Exposure Modification Lithium Reported to cause increases in serum lithium concentrations and heightened risk of lithium toxicity, due to an alteration in lithium clearance.

Official Interaction Structure

The regulatory profile documents interactions that are primarily pharmacodynamic, with the most severe constraint being the contraindication for co-administering Valt with Aliskiren in specific high-risk patient populations. Additive pharmacodynamic effects are documented for agents that increase potassium, noting the potential for hyperkalemia, and for NSAIDs, which can reduce the blood pressure-lowering effect. Furthermore, the official labeling records that co-administration can lead to a formal exposure modification of Lithium, resulting in elevated serum levels. Food does not require any mandatory timing separation, as administration is permitted with or without meals.

Mechanism of Action

How Valt Works


Modulation of Receptor-Mediated Signaling

Valt's mechanism of action involves modulating receptor- or enzyme-mediated signaling within specific biological systems. The drug acts within domains engaging mechanisms that regulate overactive or dysregulated processes.


Regulation of Downstream Effector Cascades

Valt selectively engages specific transmembrane receptors, which are integral to systems controlling specific pathway activation. This action modifies the initial molecular steps of the signaling cascade, influencing pathway activity that is responsive to external or internal stimuli.


Modification of Physiological Baseline Activity

The engagement at the receptor level initiates or suppresses specific intracellular signaling sequences. This modification alters the activity of key second messengers, influencing the function of downstream effector molecules and gene expression patterns. Through these integrated effects, Valt modifies signaling sequences that influence the regulation of physiological baseline activity, resulting in changes to systemic physiological parameters consistent with the drug's observed pharmacological profile.

Dosage and Administration Information

How to Use Valt (Valsartan): Official Administration Guidelines

Valt is administered solely via the oral route as tablets or a prepared oral suspension. Dosage and frequency are strictly dependent on the specific condition being addressed, as outlined in prescribing information.


Standard Adult Dosing and Frequency

Condition Starting Dose Maximum Daily Dose Frequency
Hypertension 80 mg or 160 mg 320 mg Once Daily (QD)
Heart Failure 40 mg 320 mg (in divided doses) Twice Daily (BID)
Post-MI Support 20 mg 320 mg (in divided doses) Twice Daily (BID)

For hypertension, the maximal reduction in blood pressure is typically attained after four weeks of therapy. For heart failure and post-MI support, the dose is initiated at a low level and gradually titrated upward to the highest dose tolerated by the patient.


Administration Requirements

Valt tablets may be taken with or without food. However, the tablets and the liquid oral suspension are not therapeutically equivalent on a milligram-per-milligram basis due to differing systemic exposure. Dose adjustment may be necessary when switching forms.

Specific instructions apply to certain patient groups:

  • Pediatric Use (6-16 years): Dosing is weight-based, starting at 1.3 mg/kg once daily (up to 40 mg total) for tablets, and use is not recommended for children under six years of age.
  • Renal/Hepatic Function: No initial dosage adjustment is typically required for older adults or patients with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Valt

Evidence for Managing High Blood Pressure (Hypertension)

Valt (valsartan) was evaluated in large-scale Randomized Controlled Trials (RCTs) and shorter-term studies to evaluate whether research indicated patterns related to blood pressure control and exploring outcomes related to long-term survival and recurrent cardiovascular events. This research primarily focused on adults with essential hypertension, but dedicated trials also included pediatric patients between the ages of 6 and 16. The long-term research explored outcomes related to physical discomfort and systemic or functional imbalance, specifically monitoring the relative frequency of major cardiovascular events. Findings report measurements of how blood pressure evolved in the observed populations.

Evidence quality for this use is considered High, primarily due to the existence of multiple large trials designed to evaluate outcomes over several years. However, the research base includes a variety of study types, and information is limited regarding long-term cardiovascular outcome patterns when valsartan is evaluated against all newer pharmacological approaches. Furthermore, data for certain groups remain insufficient, as results apply only to the older pediatric populations studied.

Evidence for Therapeutic Support in Chronic Heart Failure

Research for chronic heart failure primarily relied on large, international, double-blind Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and focused on conditions marked by functional limitations. The main outcomes studied related to systemic or functional imbalance, including the rate of hospitalizations for worsening heart failure and all-cause mortality. Studies also monitored patient-reported outcomes describing perceived discomfort and changes in functional status.

Key trials reported measurements of reduced hospitalization frequency for heart failure in the study groups. However, Evidence remains limited for the role of the combination of valsartan with both an ACE inhibitor and a beta-blocker for heart failure, as specific analyses have identified limitations in this approach. Additionally, follow-up durations were limited for long-term outcomes in heart failure with preserved ejection fraction (HFpEF), where evidence remains limited and heterogeneous compared to reduced ejection fraction (HFrEF).

Frequently Asked Questions (FAQ)

Common questions about Valt (FAQ)

Q: How quickly can a person expect to feel the effects of Valt?

Studies show that the blood pressure-lowering effect of Valt usually begins about two hours after taking a single dose. The maximal therapeutic effect, meaning the greatest reduction in blood pressure, is typically observed after four weeks of continuous therapy.

Q: What does the term 'contraindication' mean in relation to Valt?

In official medical documents, a contraindication is a specific condition or factor that indicates that use of the medicine is strictly prohibited because it would likely be harmful. For Valt, this includes severe conditions like the second and third trimesters of pregnancy, and certain co-medications. The term simply indicates a situation where the medicine is not permitted.

Q: Are there any vitamins or supplements that are known to interact with Valt?

The official interaction information points out that supplements or products containing potassium, such as some potassium supplements or certain salt substitutes, may interact with Valt. Using these concurrently may lead to an increased risk of elevated potassium levels in the blood, an effect known as hyperkalemia.

Q: Can women who are planning to become pregnant use Valt?

Official documents contain a serious safety constraint stating that Valt can harm or cause death to a developing fetus and is strictly contraindicated during the second and third trimesters of pregnancy. Women who are pregnant or are planning to become pregnant may discuss alternative options with a healthcare provider.

Q: Why are there different strengths or dosages of Valt available?

Different strengths are available to help healthcare providers personalize the treatment to a patient's needs. The official guidance often involves starting the medicine at a lower dose and gradually increasing it over time to find the most effective dose, a process often referred to as titration.

Q: Does Valt affect a person's ability to drive or operate machinery?

Because side effects like dizziness or fatigue are documented in the safety profile, the official product information notes that users may need caution. Understanding how the medicine affects an individual is noted as important before driving or operating complex machinery.

Q: Why is Valt sometimes prescribed with other medicines?

Valt is often prescribed in combination with other medicines, such as diuretics or beta-blockers, for specific conditions. Regulatory filings indicate that this combination approach is used to enhance the overall therapeutic outcome, particularly in complex conditions like chronic heart failure, to achieve better outcomes.

Q: How does the time of day affect the instructions for taking Valt?

Valt is prescribed to be taken once or twice daily, depending on the condition being treated. Official guidelines describe the importance of taking doses at approximately the same time each day to ensure a consistent amount of medicine in the body.

Q: What does 'evidence-based' mean when discussing Valt's use?

The term 'evidence-based' means that the approved uses for Valt are strongly supported by scientific data. This data is gathered through large-scale, controlled studies, known as Randomized Controlled Trials (RCTs), which must meet regulatory standards for efficacy and safety.

Q: Why might a doctor switch a patient from an old medicine to Valt?

Valt belongs to a specific class of medicine, an ARB, which has a mechanism of action that differs from other blood pressure medicines, like ACE inhibitors. The drug’s unique mechanism of action offers an alternative strategy for patients who may not tolerate other drug classes or who require a different approach to modulate blood pressure.

Q: What kind of blood tests or monitoring is usually needed while on Valt?

Regulatory documents indicate that periodic monitoring of kidney function and serum potassium levels is recommended for patients taking this medicine. This monitoring is considered important, especially for patients with heart failure or pre-existing kidney issues, due to the risk of hyperkalemia (high potassium).

Q: What is the difference between the brand name Valt and its chemical name?

Valt is the trade name used for marketing the medicine. The active ingredient is Valsartan, which is the official non-proprietary name. The chemical name is the formal, complex scientific description used for identification purposes in technical and regulatory documents.

Q: Are there specific symptoms that warrant calling a doctor immediately while taking Valt?

Regulatory safety documents list certain serious reactions, such as Angioedema (swelling of the face, lips, or throat), that require immediate attention. The documents state that these symptoms are considered serious and require immediate medical attention.

Q: How is the safety of Valt monitored after it is released to the public?

The safety of Valt is continuously monitored by regulatory bodies after it is approved and released to the public. This process is called post-marketing surveillance, where healthcare professionals and patients report adverse reactions to regulatory agencies.

Q: If I miss a dose of Valt, what is the general guidance on what to do?

Official regulatory guidance addresses the situation of a missed dose by providing instruction on when a dose should be taken if remembered, versus when it should be skipped entirely. This guidance also includes a specific caution against taking a double dose to compensate for the missed amount.

Q: Do you need to stop taking Valt gradually, or can it be stopped right away?

The official regulatory information highlights that sudden discontinuation of Valt is not advised, especially for patients being treated for heart failure or post-heart attack conditions.

Q: What happens in the body when Valt starts to wear off?

Valt is eliminated from the body with an average elimination half-life of about six hours. This means that after six hours, half of the active drug concentration has left the system, and the medicinal effect on the Angiotensin II receptor begins to diminish.

Q: What are the main things doctors consider before prescribing Valt?

Official prescribing information highlights several patient factors doctors consider, including potential drug interactions and pre-existing medical conditions. Specific factors include the status of the patient’s kidney and liver function and whether they have conditions that might cause volume depletion.

Q: If Valt is taken for a long time, does its effect lessen (tolerance)?

Long-term clinical studies examining the use of Valt for high blood pressure have been evaluated by regulatory bodies. The evidence indicates that the medicine's antihypertensive effect appeared to be maintained during the observation periods, which extended for up to two years.

Q: Is Valt a controlled substance or scheduled drug?

Based on regulatory records, Valsartan (Valt) is not listed as a controlled substance or scheduled drug by major national and international regulatory enforcement agencies. This classification means it is not subject to the strict regulations governing narcotics.

Q: What should be done if someone accidentally takes too much Valt?

The primary symptom of taking too much Valt is likely to be marked hypotension, which is severely low blood pressure. The regulatory guidance notes that supportive measures, such as lying down and fluid administration, may be considered by emergency personnel. The guidance stresses that immediate medical attention is necessary.

Q: How long does Valt stay in a person's system after the last dose?

The drug's elimination from the body is characterized by a half-life of approximately six hours. The majority of the drug and its related substances are excreted from the body via the feces and, to a lesser extent, the urine.

Q: Are there any known interactions between Valt and alcohol?

Official patient information indicates that consuming alcohol may intensify the blood pressure-lowering effect of Valt. This combination could potentially increase the chance of experiencing side effects such as dizziness or lightheadedness, and the labeling notes that this situation may require caution.

Q: What official sources provide information about Valt's safety profile?

Information regarding Valt’s safety and uses comes from government regulatory bodies. Key sources include the U.S. Food and Drug Administration (FDA) prescribing label and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

How should Valt be stored and disposed of?

How to Store and Dispose of Valt (Valsartan)

The storage and disposal of Valsartan are defined by specific regulatory requirements to maintain product integrity and safety.

Storage Conditions

Valsartan tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept away from excessive heat, moisture, and direct light in its original, closed container.

The compounded oral suspension has form-specific stability limits: it is stable for up to 75 days when refrigerated (2 C to 8 C) or up to 30 days at room temperature. The product must not be frozen in either form.

Safety and Disposal

All medicine must be stored out of the sight and reach of children and pets. Unused or expired medication should be disposed of by utilizing an official drug take-back program. If a take-back program is unavailable, follow the official guidance for mixing the product with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valt found in:

A-Z Index: